All articles tagged with #dendritic cells
Scientists have discovered that a vitamin A metabolite, retinoic acid, can suppress the immune system's ability to fight cancer by promoting immune tolerance. They developed inhibitors that block this pathway, restoring immune responses and improving cancer vaccine efficacy, paving the way for new immunotherapy treatments.
A newly isolated gut bacterium, YB328, enhances the effectiveness of PD-1 blockade immunotherapy by promoting dendritic cell migration and activating T cells, leading to improved cancer treatment responses across various tumor types, as demonstrated in patient samples and mouse models.
Israeli scientists at the Weizmann Institute of Science have developed a novel immunotherapy approach that combines T cells and dendritic cells to trigger a strong immune response against cancer. The study, published in Cell, showed promising results in reducing the growth rate of aggressive cancers in mice, and even proved effective against cancers resistant to immunotherapy. The researchers also found that the new treatment could prevent the development of secondary tumors, indicating a systemic immune response against cancer. This breakthrough offers hope for more targeted immune suppression in various diseases, and the scientists are now focused on developing a drug suitable for human treatment.
Researchers at the Weizmann Institute of Science have developed a new immunotherapy treatment that connects T cells to dendritic cells, resulting in a powerful immune response against cancerous growths. The treatment was found to be effective in reducing the growth rate of aggressive breast, lung, and skin cancers in mouse models. The new antibody, called BiCE, has shown promise in preventing the development of metastases in the lungs after the removal of the primary tumor. The institute has filed a patent application and is working on commercializing the innovative treatment, which could also have implications for autoimmune diseases.
Scientists from Harvard Medical School have developed an experimental probiotic that regulates the activity of dendritic cells, which play a crucial role in managing immune cell responses. When administered to mice with induced conditions similar to multiple sclerosis (MS), the probiotic suppressed autoimmunity in key regions of the brain. The treatment shows promise for treating chronic diseases and is more precise than existing options, with minimal side effects. The probiotic was designed to produce lactate, activating an immune system brake. The study suggests that engineered probiotics could revolutionize the treatment of autoimmune diseases and pave the way for personalized therapies.
Scientists have discovered a new mechanism by which the immune system eliminates cells lacking CD47 molecules, with dendritic cells directly killing these CD47-lacking T cells. This finding offers potential implications for cancer therapy, as it opens up the possibility of inducing cell death in cancer cells by modifying CD47. The study, conducted by researchers from Kobe University, sheds light on the previously unknown capability of dendritic cells to directly kill immune cells lacking CD47, providing a fresh perspective for future research and treatment strategies.